Tags

Type your tag names separated by a space and hit enter

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.
J Dermatolog Treat. 2007; 18(6):361-5.JD

Abstract

OBJECTIVE

A clinical trial was performed to evaluate the efficacy, speed of response, side effects and quality of life of patients treated with calcipotriol/betamethasone dipropionate (Dovobet) for 4 weeks followed by maintenance with calcipotriol for 8 weeks (group A) versus calcipotriol (Daivonex) alone for 12 weeks (group B) for the treatment of psoriasis.

MATERIALS AND METHODS

A total of 150 patients were enrolled and randomized to groups A and B. PASI and Skindex-29 were considered the outcome measures.

RESULTS

Ninety-six patients completed the trial. At weeks 2 and 4, both groups showed a significant clinical improvement compared to baseline; group A demonstrated a higher clinical response compared with group B (p< 0.001). Treatment with calcipotriol was associated with a gradual improvement in group B and maintenance of the results in group A. Similarly, the quality of life assessment showed a marked improvement in terms of Skindex-29 in both groups at weeks 2 and 4 compared to baseline. Both treatments were safe and well tolerated.

CONCLUSIONS

Our results demonstrate a higher efficacy and more rapid onset of action with the two-compound ointment compared with calcipotriol cream alone in short-term treatment. However, sequential application of calcipotriol allows maintenance of the results.

Authors+Show Affiliations

Department of Dermatology, University of Rome Tor Vergata, Viale Oxford 81, Rome, Italy. rositasaraceno@yahoo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17934937

Citation

Saraceno, Rosita, et al. "Efficacy, Safety and Quality of Life of Calcipotriol/betamethasone Dipropionate (Dovobet) Versus Calcipotriol (Daivonex) in the Treatment of Psoriasis Vulgaris: a Randomized, Multicentre, Clinical Trial." The Journal of Dermatological Treatment, vol. 18, no. 6, 2007, pp. 361-5.
Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat. 2007;18(6):361-5.
Saraceno, R., Andreassi, L., Ayala, F., Bongiorno, M. R., Giannetti, A., Lisi, P., Martini, P., Peris, K., Peserico, A., & Chimenti, S. (2007). Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. The Journal of Dermatological Treatment, 18(6), 361-5.
Saraceno R, et al. Efficacy, Safety and Quality of Life of Calcipotriol/betamethasone Dipropionate (Dovobet) Versus Calcipotriol (Daivonex) in the Treatment of Psoriasis Vulgaris: a Randomized, Multicentre, Clinical Trial. J Dermatolog Treat. 2007;18(6):361-5. PubMed PMID: 17934937.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. AU - Saraceno,Rosita, AU - Andreassi,Lucio, AU - Ayala,Fablo, AU - Bongiorno,Maria Rita, AU - Giannetti,Alberto, AU - Lisi,Paolo, AU - Martini,Patrizia, AU - Peris,Ketty, AU - Peserico,Andrea, AU - Chimenti,Sergio, PY - 2007/10/16/pubmed PY - 2008/3/26/medline PY - 2007/10/16/entrez SP - 361 EP - 5 JF - The Journal of dermatological treatment JO - J Dermatolog Treat VL - 18 IS - 6 N2 - OBJECTIVE: A clinical trial was performed to evaluate the efficacy, speed of response, side effects and quality of life of patients treated with calcipotriol/betamethasone dipropionate (Dovobet) for 4 weeks followed by maintenance with calcipotriol for 8 weeks (group A) versus calcipotriol (Daivonex) alone for 12 weeks (group B) for the treatment of psoriasis. MATERIALS AND METHODS: A total of 150 patients were enrolled and randomized to groups A and B. PASI and Skindex-29 were considered the outcome measures. RESULTS: Ninety-six patients completed the trial. At weeks 2 and 4, both groups showed a significant clinical improvement compared to baseline; group A demonstrated a higher clinical response compared with group B (p< 0.001). Treatment with calcipotriol was associated with a gradual improvement in group B and maintenance of the results in group A. Similarly, the quality of life assessment showed a marked improvement in terms of Skindex-29 in both groups at weeks 2 and 4 compared to baseline. Both treatments were safe and well tolerated. CONCLUSIONS: Our results demonstrate a higher efficacy and more rapid onset of action with the two-compound ointment compared with calcipotriol cream alone in short-term treatment. However, sequential application of calcipotriol allows maintenance of the results. SN - 0954-6634 UR - https://www.unboundmedicine.com/medline/citation/17934937/Efficacy_safety_and_quality_of_life_of_calcipotriol/betamethasone_dipropionate__Dovobet__versus_calcipotriol__Daivonex__in_the_treatment_of_psoriasis_vulgaris:_a_randomized_multicentre_clinical_trial_ L2 - https://www.tandfonline.com/doi/full/10.1080/09546630701646156 DB - PRIME DP - Unbound Medicine ER -